Table 1. Key clinical data.
| Parameter | Values (ranges) | Description and Reference |
|---|---|---|
| Weibull survival model of PFS of crizotinib in Chinese cohort | Scale = 0.0211; Shape = 1.5326; r2 = 0.972 | Solomon et al., 2014 |
| Weibull survival model of PFS of PC in Chinese cohort | Scale = 0.0663; Shape = 0.8604; r2 = 0.991 | Solomon et al., 2014 |
| HR of survival of chemotherapy versus supportive care | 0.77(0.83–0.71) | NSCLC Meta-Analyses Collaborative Group, 2008 |
| Probability of progressed survival | 0.086(0.08–0.093) | Hayashi et al., 2012 |
| ALK prevalence | 0.065(0.014–0.116) | Wu et al., 2013 |
| Body surface (m2) | 1.72(1.5–1.9) | Wu et al., 2011 |
| NGS panel tests | ||
| Sensitivity | 1(0.95–1) | Lin et al., 2016 |
| Specificity | 1(0.95–1) | Lin et al., 2016 |
| Multiplex PCR testing | ||
| Sensitivity | 1(0.95–1) | Marchetti et al., 2016 |
| Specificity | 1(0.95–1) | Marchetti et al., 2016 |
ALK: anaplastic lymphoma kinase; HR: hazard ratio; NGS: next-generation sequencing; NSCLC: non-small-cell lung cancer
PC: pemetrexed plus cisplatin; PFS: progression-free survival; PCR: polymerase chain reaction